Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 18/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1327937 | 0.97 | OPRM1 (0.45) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL1328910 | 0.85 | CRHR1 (0.38) | DRD2 | |
| SCHEMBL1329547 | 0.85 | OPRM1 (0.43) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL1327894 | 0.83 | OPRM1 (0.46) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL1327781 | 0.83 | OPRM1 (0.46) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL1328474 | 0.82 | OPRM1 (0.46) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL2142640 | 0.82 | OPRM1 (0.45) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL1327691 | 0.80 | BCHE (0.42) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL1327934 | 0.80 | OPRM1 (0.45) | OPRM1OPRK1OPRD1DRD2DRD3 | |
| SCHEMBL2139525 | 0.79 | OPRM1 (0.48) | OPRM1OPRK1OPRD1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | OPRM1 674/4885OPRK1 475/4885OPRD1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.